# NCT04793958 (NCT04793958)

> Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04793958
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Advanced Colorectal Cancer; Metastatic Colorectal Cancer
- Interventions: MRTX849; Cetuximab; mFOLFOX6 Regimen; FOLFIRI Regimen
- Enrollment: 461
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- X threads: 14
- Podcasts: 13
- YouTube: 12

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04793958

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04793958", "email": "<work email>"}; the inbox owner confirms by the emailed link.